

MECTEST EIA by FPIA

Intended Use

MECTEST EIA by FPIA is a device intended for processing meconium into a suitable form for the analysis of cocaine or opiate by fluorescence polarization immunoassay (FPIA). Specifically:

- MECTEST EIA is a meconium processor only
- After processing meconium, the product can be analyzed for cocaine or opiate by fluorescence polarization immunoassay (FPIA using the Abbott ADX fluorescence polarization immunoassays for cocaine or opiate (additional information is available from Abbott Laboratories, Abbott Park IL).

Note: The MECTEST EIA by FPIA **does not contain** the FPIA reagents for cocaine or opiate analysis.

- Cut-off concentrations for cocaine and opiate in meconium by FPIA are shown.

	FPIA (ng/mL)
Cocaine	25
Opiate	25

Substantial Equivalence

Substantial equivalence of FPIA to radioimmunoassay for the analysis of cocaine and opiate in meconium are presented below (see clinical study). Analysis of meconium for cocaine, opiate and cannabinoid by MECTEST radioimmunoassay is an FDA cleared method (information on MECTEST radioimmunoassay is available from Mectest Corporation, Rowland Heights, CA).

Materials and Reagents Required

- The MECTEST EIA is a meconium processor which consists of a meconium container, a scoop and an ultrafilter. The meconium container contains a solvent, which has methanol. Avoid prolonged inhalation of vapor.
- FPIA assays
 - Abbott ADX Reagent Kit for Cocaine Metabolite
 - Abbott ADX Reagent Kit for Opiate

Materials Provided

- Meconium processor:
 - 12 tubes, each containing meconium scoop and 5ml of solvent
 - 12 ultrafilters

Materials Required But Not Provided

- Abbott ADX Reagent Kit for Cocaine Metabolite (available from Abbott Laboratories, Abbott Park, IL)
 - Reagent pack
 - FPIA calibrators (benzoylecgonine) at 0, 500 and 1000 ng/mL
- Abbott ADX Reagent Kit for Opiates (available from Abbott Laboratories, Abbott Park, IL)
 - Reagent pack
 - FPIA calibrators (morphine at 0, 100, 250 and 350 ng/mL)
- Liquid Tox Control (0, 120, 350 ng/mL)
- Meconium positive and negative controls

Specimen Collection and Preparation

Meconium is a dark to greenish yellow stool and is passed during the first 3 days after birth in fullterm infants or even days later in premature infants. Bright yellow stool is not meconium and should not be used for drug analysis. Meconium is a biologic specimen. Observe universal precautions, including the use of gloves, in the collection and processing of meconium to prevent the transmission of diseases, particularly hepatitis and AIDS.

Collect meconium directly from the infant's diaper. Meconium should be mixed well in the diaper before a sample is taken since drugs are not uniformly distributed in meconium. Drug concentrations in meconium will significantly decrease if meconium is allowed to stand at room temperature for 24 hours (see below). Thus, meconium should be sampled and analyzed within 12 hours after it is excreted by the infant.

Specimen stability and storage: The stability of drugs (cocaine, morphine and cannabinoid) in meconium was studied using quantitative radioimmunoassay.

- Meconium allowed to stand at room temperature for 24 hours resulted in a 25% decrease in cocaine. Thus, meconium should be sampled and processed as soon as possible after its excretion by the infant to prevent loss of drugs.
- There is no drug loss in meconium suspended in MECTEST meconium processor solvent at room temperature for at least 72 hours. Meconium should therefore be mixed well in the solvent after sampling and if left at room temperature, should be tested within 72 hours. Meconium can also be transported without refrigeration, for at least 72 hours, if suspended in MECTEST solvent.
- For prolonged storage and drug stability, drugs are stable in meconium at 15°C for as long 9 months.

Procedure for the Preparation and Analysis of Cocaine and Morphine in Meconium

A. Meconium Collection

- Mix meconium in infant's diaper before sampling. Pooling of meconium from several diapers before sampling will increase the detection rate of drugs in meconium.
- Unscrew cap of meconium processor. Set tube in rack (do not spill reagent). Use scoop attached to the cap to obtain 0.5 g of meconium (approximately one scoopful of meconium).
- Place cap and scoop containing meconium back into the meconium processor.
- Screw cap tightly.

Note: If meconium is sent to an outside laboratory for analysis, meconium should be vortexed and emulsified in meconium solvent (see Meconium Processing, Step 1) prior to mailing.

B. Meconium Processing:

- Vortex meconium processor using scoop as a stirrer until meconium is evenly dispersed in the solvent. (To test, lay tube on its side – globs of meconium should not be seen).
- Detach scoop from cap and discard scoop.
- Recap tube and centrifuge at 4600 rpm (3000 g) for 30 minutes.
- Collect supernate and transfer 1 mL into the ultrafilter provided in the kit. (Save remaining supernate for future use).
- Centrifuge at 4600 rpm (3000 g) for 30 minutes. Let stand for 10 minutes to avoid overheating. Centrifuge at 4600 rpm for another 30 minutes.
- Collect total ultrafiltrate (approximately 250 microliters) for drug analysis.

C. Preparation of Standards and Meconium Controls

- FPIA analysis for cocaine
 - Prepare cocaine standards at 0, 25, and 250 ng/mL. Dilute calibrators with zero calibrator for the desired concentrations.
 - Tox Control at 0, 115, 340 ng/mL. (Available from Medical Analysis System, Camarillo, CA).
- Meconium controls
 - Negative meconium control: Obtain 0.5 g of drug free meconium. Process meconium as above.
 - Positive meconium control (30 ng/mL): Obtain 0.5 g of drug free meconium. Add 0.150 mL of FPIA Calibrator C (1000 ng/mL). Process meconium as above.
- FPIA analysis for opiate
 - Prepare opiate standards at 0, 25 and 250 ng/mL. Dilute calibrators with zero calibrator for desired concentrations.
 - Tox Control at 0, 120, 350 ng/mL. (Available from Medical Analysis System, Camarillo, CA).
- Meconium controls
 - Negative meconium control: Obtain 0.5 g of drug free meconium. Process as above.
 - Positive meconium control (30 ng/mL): Obtain 0.5 g of drug free meconium. Add 0.5 mL of FPIA Calibrator D (350 ng/mL). Process meconium as above.

D. Procedure for Meconium Drug Analysis by FPIA

1. Set drug standards for calibration.
2. Use 25 microliters of Tox Control and ultrafiltrates from meconium control and patient meconium for each drug analysis.
3. Analyze meconium ultrafiltrates and controls for cocaine and opiate by ADX FPIA (information on FPIA assay is available from Abbott Laboratories, Abbott Park, IL).

Reporting of Results

Positive Results

The cutoff concentrations for cocaine or opiate by FPIA are shown in the table below. A sample that gives a change in absorbance (AA) value equal to or higher than the AA value of the 25 ng/mL standard is interpreted as a preliminary positive result.

Note: A positive test is a preliminary result only and should be confirmed by a more specific method. Gas chromatography/mass spectrometry (GCMS) is the preferred method of confirmation.

Cutoff concentrations for cocaine and opiate by FPIA

	FPIA (ng/mL)
Cocaine	25
Opiate	25

Negative Results

The cutoff concentrations for cocaine or opiate by FPIA are shown in the table below. A sample that gives a change in absorbance (AA) value lower than the AA value of the 25 ng/mL standard is interpreted as negative.

Cutoff concentration for cocaine and opiate by FPIA

	FPIA (ng/mL)
Cocaine	25
Opiate	25

Warning: A negative result does not eliminate the possibility of drugs of abuse consumption by the mother. When meconium is used in any other system/method for the detection of drugs of abuse, the user must be aware that the concentration of the drug of abuse in meconium has not been correlated with the dose of the drug of abuse consumed by the mother, nor with the clinical picture in the neonate. The performance characteristics of other systems/methods have not been determined by the manufacturer nor have been FDA cleared.

Performance Characteristics

A. Sensitivity

1. Fluorescence Polarization Immunoassay (FPIA)

a) *Cocaine.* The sensitivity of the MECTEST EIA by FPIA for cocaine was determined by spiking meconium with different amounts of benzoylecgonine (BE) and analyzing the different concentrations by FPIA: 0.5g of drug free meconium was suspended in 5 mL of solvent in the MECTEST processor. The mixture was vortexed for 5 minutes. Known amounts of benzoylecgonine were added to the meconium suspension to achieve concentrations ranging from 0 to 100 ng/mL. A positive FPIA test was seen at benzoylecgonine concentration of 25 ng/mL as shown in the table below. Since FPIA is a qualitative test, a benzoylecgonine concentration in meconium of at least 25 ng/mL is recommended as the cutoff concentration for a positive test.

BE concentration (ng/mL)	FPIA
0	-
0	-
0	-
25	+
25	+
50	+
50	+
100	+
100	+

- b) *Morphine.* The sensitivity of the MECTEST EIA by FPIA for morphine was determined by spiking meconium with different amounts of morphine and analyzing the different concentrations by FPIA: 0.5 g of drug free meconium was suspended in 5 mL of solvent in the MECTEST processor. The mixture was vortexed for 5 minutes. Known amounts of morphine were added to the meconium suspension to achieve concentrations ranging from 0 to 100 ng/mL. A positive FPIA test was seen at morphine concentration of 25 ng/mL. Since FPIA is a qualitative test, a morphine concentration in meconium of at least 25 ng/mL is recommended as the cutoff concentration for a positive test.

Morphine concentration (ng/mL)	FPIA
0	-
0	-
0	-
25	+
25	+
50	+
50	+
100	+
100	+

B. Specificity

1. Fluorescence Polarization Immunoassay (FPIA)

Meconium was found to contain endogenous amounts of bilirubin (60.23 ± 2.76 micrograms/gm meconium), blood 0 to +++ hemoglobin by qualitative guaiac test) and protein (32.89 ± 12.36 mg/gm meconium) which did not interfere in the detection of benzoylecgonine or morphine in meconium. In meconium spiked with cocaine, opiate and cannabinoid, cross reaction was not seen between the drugs when analyzed by FPIA and radioimmunoassay (RIA).

Drug concentration (ng/mL)			Cocaine detection by		Morphine detection by	
Morphine	Cocaine	Cann	RIA	FPIA	RIA	FPIA
100	100	100	+	+	+	+
100	100	0	+	+	+	+
100	0	100	-	-	+	+
0	100	100	+	+	-	-
200	200	200	+	+	+	+
200	200	0	+	+	+	+
200	0	200	-	-	+	+
0	200	200	+	+	-	-

C. Accuracy

1. Fluorescence Polarization Immunoassay (FPIA)

- a) *Interassay precision.* Determination of drug concentrations of 6 meconium samples, each spiked either with 50 or 100 ng/mL of cocaine and morphine showed mean coefficient of variable of 0.78 ± 0.11 % for cocaine and 0.44 ± 0.02 % for morphine.
- b) *Intra-assay precision.* Triplicate analysis for cocaine and morphine were done in 4 meconium samples. A coefficient of variable was obtained for each triplicate analysis. The mean (sd) coefficient variability was 0.34 ± 0.19 % for cocaine and 0.43 ± 0.11 % for morphine.

D. Clinical Study

1. Fluorescence Polarization Immunoassay (FPIA)

For substantial equivalence, FPIA was compared to RIA in 61 samples and in 20 additional samples, FPIA was also compared to GC/MS.

a) *Cocaine*. Meconium was obtained from 61 infants and analyzed for cocaine by FPIA and RIA. The concordance of positive and negative results were 98 and 95, respectively.

FPIA	Radioimmunoassay		Total
	Negative	Positive	
Negative	21	1	22
Positive	1	38	39
Total	22	39	61

Concordance of positive results = 38/39 (98%)

Concordance of negative results = 21/22 (95%)

Meconium was obtained from 20 infants and analyzed for cocaine by FPIA and GC/MS. The following results show 100% concordance of positive and negative tests by the 2 methods.

No.	FPIA	GCMS	No.	FPIA	GCMS
1	+	+	11	+	+
2	+	+	12	+	+
3	+	+	13	+	+
4	+	+	14	+	+
5	+	+	15	-	-
6	+	+	16	-	-
7	+	+	17	+	+
8	+	+	18	+	+
9	+	+	19	+	+
10	+	+	20	+	+

c) *Opiate*. Meconium was obtained from 61 infants and analyzed for opiate by FPIA and RIA. The concordance of positive and negative results were 100% and 98%, respectively.

FPIA	Radioimmunoassay		Total
	Negative	Positive	
Negative	52	0	52
Positive	1	8	9
Total	53	8	61

Concordance of positive results = 8/8 (100%);

Concordance of negative results = 52/53 (98%)

2) Meconium was also obtained from 20 infants and analyzed for morphine by FPIA and GC/MS. The results show high concordance between positive and negative tests by the 2 methods as shown in the following table.

No	FPIA	GCMS	No.	FPIA	GCMS
1	+	+	11	+	+
2	+	+	12	-	-
3	+	+	13	+	+
4	-	-	14	+	+
5	+	+	15	+	+
6	+	+	16	+	+
7	+	+	17	+	+
8	+	+	18	+	+
9	+	+	19	+	+
10	+	+	20	-	-

E. Effect of Carryover

Patient samples may occasionally have very high concentrations of cocaine or morphine. It is suggested that routine precautions be taken, e.g., employing a fresh pipet tip for each sample, to avoid carry-over contamination.

F. Limitations: Based on a review of the literature, the following may cause false positive reactions:

1. Maternal medications containing morphine, codeine or other opioids
2. Maternal ingestion of food or drinks containing poppy products or coca products (such as herbal tea).
3. Passive maternal inhalation of cocaine, opiate.
4. Technical or procedural errors.

G. Quality Control

1. *Record keeping*. It is good laboratory practice to record for each assay the lot numbers and reconstitution dates of the components used.
2. *Sample handling* It is good laboratory policy to maintain accurate chain of custody of specimens. The instructions for the proper collection, handling and storage of samples should be followed. Criteria for non acceptance of specimen, include: a) improperly identified specimen, b) leakage of specimen container, c) broken container. The instructions for handling and storing patient samples and components should be carefully observed. Dilute high patient samples with the kit's zero calibrator prior to assay. All samples, including the calibrators and controls, should be assayed in duplicate. It is good laboratory practice to use a disposable-tip micropipet, changing the tip between samples, in order to avoid carry-over contamination.
2. *Controls*. We recommend that in accordance with guidelines set by the National Institute on Drug Abuse, controls should be assayed at or near the cutoff concentrations and the results charted from day to day.

H. Clinical Application

The analysis of drugs and their metabolites in meconium is a new and sensitive method for identifying infants who have been exposed to drugs in utero .¹⁻² Meconium represents the first series of green stools of the newborn infant which are passed within a few days after birth. The concept behind meconium testing was based on initial research in animals which showed that a high concentration of the drugs which the pregnant animal was exposed to, were present in the meconium of their fetuses. ²⁻⁵ Drugs which the fetus is exposed to during pregnancy are metabolized by its liver into water soluble metabolites and excreted into the bile or urine. It is postulated that drug deposition in meconium occurs either through

bile secretion or through swallowing by the fetus of its urine via the amniotic fluid. Clinical studies in humans have validated meconium analysis as a sensitive drug screen in the newborn infant.⁶⁻⁹ The initial clinical study compared drug detection in 20 infants of drug dependent mothers by meconium and urine analysis.¹ Whereas all meconium samples contained either cocaine, opiate or cannabinoid, only 37% of the urine tested was positive for these drugs. Subsequent studies have corroborated the sensitivity of meconium drug testing. In one study, meconium was analyzed for cocaine, morphine, codeine and marijuana from 28 neonates born to women suspected of drug abuse.⁹ In each case, testing of urine from the mother, the infant or both were done because of suspected maternal drug abuse. Compared with the combination of maternal and newborn urine testing, meconium testing had an 82% positive predictive value and a 91% negative predictive value. The authors further added that the collection of meconium was simpler and more reliable than collection of urine and that the testing of meconium was easily incorporated into routine procedures at a busy commercial laboratory. In another study, a comparison of the sensitivity of meconium and urine analyses for drugs in detecting gestational exposure to cocaine was studied.⁸ The infants were born to 59 women who were interviewed to determine their use of cocaine during pregnancy. Radioimmunoassay and gas chromatography of meconium were more sensitive than immunoassay of urine ($p < 0.02$). Urine immunoassay failed to identify 60% of cocaine exposed infants. The largest clinical study using meconium drug testing was a drug prevalence study conducted in a large, high risk, obstetric population. The superiority of meconium testing over maternal history was demonstrated. A fourfold (44.3% vs 11.1%) higher incidence of drug exposure was found among 3010 infants tested by meconium analysis as compared to maternal history. The meconium drug test has also been adapted for mass drug screening of newborn infants¹⁰ and selection criteria for routine testing of infants have been formulated.

Recently, other studies have been published illustrating the clinical application of the meconium drug test. The meconium test was used to prospectively screen for drugs (opiates, cocaine and cannabinoids) every infant who was admitted to the neonatal intensive care unit of a high risk perinatal center for a 3 month period.¹² Of the 82 infants tested, 41 or 50% were positive for drugs: 36 (44%) positive for cocaine, 9 (11%) positive for opiates and none for cannabinoid. The total cost for the care of these infants was \$1,223,750. The authors concluded that there is a high prevalence of drug exposure in infants admitted to the neonatal intensive care and that the morbidity, mortality and medical cost, associated with drugs, are significant. A biologic marker of fetal exposure to nicotine in passive and active maternal smoking has also been determined by meconium analysis.¹³ Nicotine metabolites (cotinine and trans 3'-hydroxycotinine) were detected in meconium at concentrations proportional to the degree of maternal active and passive smoking. Furthermore, in utero exposure to tobacco smoke in infants of passive smokers was as high as among infants whose mothers actively smoked less than 1 pack per day during pregnancy. Lastly, a comparative methodologic study was done to detect in utero cocaine exposure in infants. Maternal history was compared with various assays in meconium, Maternal urine and infant's urine, using GC/MS, EMIT, ADx and DPC radioimmunoassay. The authors found meconium to be superior to either maternal or infant urine in detecting in utero cocaine exposure, although the need for concomitant maternal histories in some cases was emphasized.

In summary, meconium drug testing is ideal in the newborn period for several reasons: (i) the test is highly sensitive and specific, (ii) the test can be performed using common laboratory techniques for purposes of mass screening and with capabilities for GC/MS confirmation, (iii) collection of meconium is easy and non invasive, (iv) analysis of serial meconium can reflect the type, chronology and amount of in utero drug exposure of the infant is and, (v) drugs in meconium are present up to the third day after birth; thus late testing of the infant for drugs is possible. Meconium drug testing has therefore become a useful tool for clinical and research needs.

References

- Ostrea EM, Parks P, Brady M. Rapid isolation and detection of drugs in meconium of infants of drug dependent mothers. *Clin Chem* 1988; 34: 2372-2373.
- Ostrea EM, Brady MJ, Parks PM, Asensio DC, Naluz A. Drug screening of meconium in infants of drug dependent mothers. An alternative to urine testing. *J Pediatr* 1989; 115:474-477.
- Ostrea EM, Lynn SN, Wayne RFL, Stryker JC. Tissue distribution of morphine in the newborns of addicted monkeys and humans. *Dev Pharmacol Ther* 1980;1:163-170
- Lucena J, Silvestre MA, Raymundo AL, Roxas R, Ostrea EM. The effect of timing, dosage and duration of cocaine intake during pregnancy on the amount of cocaine in meconium in a rat model. *Pediatr Res* 1991;29:62A.
- Silvestre MA, Lucena J, Ostrea EM. The effect of timing, dosage and duration of morphine intake during pregnancy on the amount of morphine in meconium in a rat model. *Biol Neonate* 1997;72: 112-117
- Ostrea EM, Brady MJ, Gause S, Raymundo AL, Stevens M. Drug screening of newborns by meconium analysis: A large scale, prospective, epidemiologic study. *Pediatrics* 1992; 89:107-113.
- Ostrea EM, Martier S, Welch R, Brady MJ. Sensitivity of meconium drug screen in detecting intrauterine drug exposure of infants. *Pediatr Res* 1990; 27:219A.
- Callahan CK, Grant TK, Phipps P, Clark G et al. Measurement of gestational cocaine exposure: Sensitivity of newborn hair, meconium and urine. *J Pediatr* 1992;120:763-8.
- Maynard EC, Amuroso LP, Oh W. Meconium for drug testing. *Amer J Dis Child* 1991;145:650-652.
- Ostrea EM, Romero A. Adaptation of the meconium test for mass drug screening. *J Pediatr* 1993;122:152-154.
- Ostrea EM, Romero A. Selection criteria for routine drug screening of infants by meconium analysis. *Pediatr Res* 1992;31:215A.
- Ostrea EM, Lizardo E, Tanafranca M. The prevalence of illicit drug exposure in infants in the NICU as determined by meconium drug analysis. *Pediatr Res* 1992;31:215A.
- Knapp DK, Ostrea EM, Romero A. Fetal exposure to nicotine in passive and active maternal smoking as detected by meconium analysis. *J Pediatr* 1994;124:471-6.
- Bandstra ES, Steele BW, Chitwood DD et al. Detection of in utero cocaine exposure: A comparative methodologic study. *Pediatr Res* 1992;31:58A.
- Ostrea EM, Knapp DK, Ostrea AR, Tannenbaum L, Salari V. A prospective study comparing systematic interview and analysis of maternal hair and meconium to determine illicit drug use during pregnancy. *Pediatr Res* 1994;35:245A
- Montes M, Romero A, Ostrea EM, Ostrea AR. Improved method of GC/MS analysis of meconium for opiate, cocaine and cannabinoid. *Pediatr Res* 1993;33:66A.